Opko Health, Inc 10-Q for FY2026 Q3
Opko Health, Inc. (OPK)
10-Q
2026-11-04
For: 2026-09-30
View Original
Added on
November 04, 2026
About this 10-Q
Opko Health, Inc filed this 10-Q on November 4, 2026, covering the quarter ended September 30, 2026 (FY2026 Q3).
Opko Health plans to sell substantially all remaining BioReference diagnostic operations to Laboratory Corporation of America Holdings, while nine-month revenue rose 30% to $206.5 million and operating loss fell 32% to $81.4 million. AI summary
Headline figures
Quarter ended September 30, 2026, as reported in this filing, compared with the same period a year earlier where the filing states it.
- Revenue
- $65.41M
- up 15.9% from $56.43M a year earlier
- Net loss
- $53.53M
- compared with net income of $21.63M a year earlier
- Diluted EPS
- -$0.07
- compared with $0.03 a year earlier